Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

F7751

Sigma-Aldrich

Fluoxymesterone

solid (photosensitive)

Synonym(s):

11β,17β-Dihydroxy-9α-fluoro-17α-methyl-4-androsten-3-one, 9α-Fluoro-11β,17β-dihydroxy-17α-methylandrost-4-en-3-one, 9α-Fluoro-11β-hydroxy-17α-methyltestosterone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H29FO3
CAS Number:
76-43-7
Molecular Weight:
336.44
EC Number:
200-961-8
MDL number:
MFCD00010480
UNSPSC Code:
51111800
PubChem Substance ID:
24894947

biological source

Porcine pancreas
bovine milk (other parts like skeletal muscle/bile/bone/connective tissue/skin)
microbial (Mycobacterium sp.)

form

solid (photosensitive)

drug control

USDEA Schedule III; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

color

white

solubility

H2O: ≤0.5 mg/mL
45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 6.4 mg/mL
ethanol: 7.3 mg/mL

application(s)

forensics and toxicology
veterinary

shipped in

ambient

storage temp.

room temp

SMILES string

[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1

InChI key

YLRFCQOZQXIBAB-RBZZARIASA-N

Gene Information

human ... AR(367) , ESR1(2099) , PRLR(5618)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Fluoxymesterone is an androgen and anabolic steroid.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Precautionary Statements

P281

Hazard Classifications

Repr. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
107F0814
069H1210
062H0194
057H1128
020H0318

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A A Welder et al.
Journal of pharmacological and toxicological methods, 33(4), 187-195 (1995-08-01)
Hepatic complications in athletes and bodybuilders after abusing anabolic-androgenic steroids (AAS) have been reported. Hepatic injury, including cholestasis, peliosis hepatis, hyperplasia, and tumors, have been attributed to abuse of the 17 alpha-alkylated AAS. Some of these pathological conditions have been
G W Sledge et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18(2), 262-266 (2000-01-19)
Although hormonal therapy represents standard therapy for metastatic hormone-sensitive disease, many patients receive initial chemotherapy because of the location, bulk, or aggressiveness of their disease. It is uncertain whether simultaneous hormonal therapy provides additional benefit compared with chemotherapy alone. Eastern
M Perloff et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14(5), 1589-1598 (1996-05-01)
To compare two cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) regimens with a doxorubicin-based regimen--vinblastine, doxorubicin, thiotepa, and Halotestin (Upjohn, Kalamazoo, MI) (VATH)--in patients with stage II node-positive breast carcinoma. Nine hundred forty-five women were treated with a 6-week induction
M V Bernardo et al.
Statistics in medicine, 20(4), 557-579 (2001-02-27)
In this paper we propose formulae for calculating the expected number of events or, alternatively, the required trial duration, for clinical trials involving two treatment groups in which patients may potentially experience multiple events and the data will be analysed
L Del Mastro et al.
Breast cancer research and treatment, 43(2), 183-190 (1997-04-01)
The role of amenorrhea induced by chemotherapy in premenopausal women with early breast cancer is very controversial. Analyses by various authors of the effect of drug-induced amenorrhea (DIA) on treatment outcome have yielded conflicting results. In order to gain insight
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service